The interaction of HAdV-C5 and many other adenoviruses with blood coagulation factors (e.g. human factor X; FX) involves the binding of their GLA domain to the hexon capsomers, resulting in high levels of hepatotropism and potential hepatotoxicity. In this study, we tested the possibility of preventing these undesirable effects by using a GLA mimicking peptide as a competitor. A FX GLA domain-derived, 40-mer polypeptide carrying 12 carboxyglutamate residues was synthesized (GLAmim). SPR analysis showed that GLAmim reacted with free and capsid-embedded hexon with a nanomolar affinity. Unexpectedly, GLAmim failed to compete with FX for hexon binding, and instead significantly increased the formation of FX-hexon or FX-adenovirion complexes. This observation was confirmed by in vitro cell transduction experiments using HAdV-C5-Luciferase vector (HAdV5-Luc), as preincubation of HAdV5-Luc with GLAmim prior to FX addition resulted in a higher transgene expression compared to FX alone. HAdV-C5 virions complexed with GLAmim were analyzed by cryo-electron microscopy. Image reconstruction demonstrated the bona fide hexon-GLAmim interaction, as for the full-length FX, although with considerable differences in stoichiometry and relative location on the hexon capsomer. Three extra densities were found at the periphery of each hexon, whereas one single FX molecule occupied the central cavity of the hexon trimeric capsomer. A refined analysis indicated that each extra density is found at the expected location of one highly variable loop 1 (HVR-1) of the hexon, involved in scavenger receptor recognition. HAdV5-Luc complexed with a bifunctional GLAmimRGD peptide showed a lesser hepatotropism, compared to control HAdV5-Luc alone, and efficiently targeted αβ-integrin overexpressing tumor cells in an in vivo mouse tumor model. Collectively, our findings open new perspectives in the design of adenoviral vectors for biotherapy.
